Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial

Trine Zeeberg Buch-Hansen, Rikke Bæk Sørensen, A. Mellemgaard, P.T. Straten, M.H. Andersen, I.M. Svane, M.H. Andersen

    Original languageEnglish
    JournalJournal of Immunotherapy
    Volume33
    Issue number8
    Pages (from-to)919-920
    Number of pages2
    ISSN1524-9557
    Publication statusPublished - 2010

    Cite this